The company plans to submit orforglipron for approval as an obesity medication to global regulatory agencies by the end of the year, and as a diabetes medication in 2026
Adding cagrilintide raises the GI tolerance bar further
Six 5-week-old female BALB/c mice bearing tumors were randomly assigned into two groups
Victoza, also containing liraglutide, is primarily used for diabetes management but can provide weight loss benefits as well
Prolonged action of incretin hormones By preventing their breakdown, these drugs increase levels of active GLP-1 and GIP in the bloodstream
Symptoms include dizziness, sweating, confusion, and extreme hunger Severe side effects: Nausea or vomiting that prevents eating, severe abdominal pain, or other side effects affecting nutrition Binge eating episodes: Uncontrollable eating despite the medication Your healthcare provider may need to adjust your dose, check for other medical conditions, or provide additional support strategies